Crispr Therapeutics (NASDAQ:CRSP) had its price objective lifted by Oppenheimer from $65.00 to $80.00 in a report issued on Monday, November 25th, The Fly reports. The firm currently has an outperform rating on the stock. Oppenheimer also issued estimates for Crispr Therapeutics’ FY2019 earnings at $0.59 EPS, Q1 2020 earnings at ($0.89) EPS, Q2 2020 earnings at ($0.97) EPS, Q3 2020 earnings at ($1.32) EPS, Q4 2020 earnings at ($1.42) EPS, FY2020 earnings at ($4.63) EPS, FY2021 earnings at ($4.47) EPS, FY2022 earnings at ($4.98) EPS and FY2023 earnings at ($2.03) EPS.
CRSP has been the topic of several other reports. ValuEngine upgraded Crispr Therapeutics from a sell rating to a hold rating in a research report on Friday, November 1st. Chardan Capital reiterated a buy rating and set a $72.50 price target on shares of Crispr Therapeutics in a research report on Monday, November 18th. Barclays lifted their price target on Crispr Therapeutics from $59.00 to $62.00 and gave the company an overweight rating in a research report on Tuesday, July 30th. BTIG Research lifted their price target on Crispr Therapeutics from $51.00 to $59.00 and gave the company a positive rating in a research report on Tuesday, July 30th. Finally, Jefferies Financial Group initiated coverage on Crispr Therapeutics in a research report on Thursday, August 1st. They set a buy rating and a $64.00 price target on the stock. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and fourteen have given a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $69.54.
CRSP opened at $65.95 on Monday. Crispr Therapeutics has a 12 month low of $22.22 and a 12 month high of $74.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. The stock has a market cap of $3.61 billion, a P/E ratio of -19.17 and a beta of 3.30. The stock’s 50 day moving average price is $61.00 and its 200 day moving average price is $49.02.
Crispr Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, beating the consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The firm had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million. Equities analysts anticipate that Crispr Therapeutics will post 0.65 EPS for the current year.
In other news, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now directly owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the sale, the director now directly owns 7,500 shares of the company’s stock, valued at $412,500. The disclosure for this sale can be found here. Over the last three months, insiders have sold 56,118 shares of company stock valued at $3,620,760. Corporate insiders own 21.40% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in CRSP. Nikko Asset Management Americas Inc. boosted its stake in shares of Crispr Therapeutics by 324.3% during the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,871,408 shares of the company’s stock worth $88,143,000 after acquiring an additional 1,430,364 shares in the last quarter. ARK Investment Management LLC boosted its position in shares of Crispr Therapeutics by 34.7% in the second quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock worth $128,317,000 after buying an additional 701,332 shares during the period. Orbimed Advisors LLC acquired a new stake in shares of Crispr Therapeutics in the third quarter worth $21,167,000. Price T Rowe Associates Inc. MD boosted its position in shares of Crispr Therapeutics by 19.6% in the second quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after buying an additional 121,176 shares during the period. Finally, Wells Fargo & Company MN boosted its position in shares of Crispr Therapeutics by 23.9% in the second quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after buying an additional 116,540 shares during the period. 49.82% of the stock is owned by institutional investors and hedge funds.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: Using the New Google Finance Tool
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.